logo-loader
viewMindMed

MindMed aims to curb opioid abuse and treat ADHD patients with its psychedelic inspired medicines

MindMed Inc. (NEO: MMED) (OTCQB: MMEDF) CEO JR Rahn tells Proactive the New York-based psychedelic inspired medicines company is aiming to curb opioid abuse and treat ADHD dependent patients with its psychedelic inspired medicines.

Rahn says the coronavirus pandemic is likely to increase 'profound mental health and addiction issues' where MindMed would be well setup to address these ongoing issues.

Quick facts: MindMed

Price: 0.3878 USD

OTCQB:MMEDF
Market: OTCQB
Market Cap: $76.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MindMed named herein, including the promotion by the Company of MindMed in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MindMed investigating potential benefits of DMT in upcoming Phase 1 clinical...

Mind Medicine Inc (NEO:MMED) (OTCQB:MMEDF) CEO JR Rahn tells Proactive it is pursuing research into DMT, the active ingredient in Ayahuasca. Rahn says its part of a research and development collaboration that the psychedelics company has with the University Hospital Basel’s Liechti Lab....

on 06/19/2020

2 min read